Provexis plc (FRA:NZCA)

Market Cap	26.62M +60.5%
Revenue (ttm)	1.45M -2.1%
Net Income	-575.78K
EPS	-0.00
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	22,000
Open	0.0075
Previous Close	0.0070
Day's Range	0.0075 - 0.0075
52-Week Range	0.0005 - 0.0150
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Oct 30, 2026

About Provexis

Provexis plc, together with its subsidiaries, develops, licenses, and sells functional foods, medical foods, and dietary supplements worldwide. It provides syrup and powder versions of Fruitflow, a tomato extract that reduces the propensity for aberrant blood clotting typically associated with cardiovascular diseases, such as heart attack and stroke used in various foods, beverages, and dietary supplement formats. The company also provides Fruitflow+ Omega-3, a dietary supplement product. It sells its products through e-commerce website and dis...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1999
• Employees: 2
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: NZCA

Financial Performance

In fiscal year 2026, Provexis's revenue was 1.26 million, a decrease of -2.14% compared to the previous year's 1.29 million. Losses were -502,760, 11.1% more than in 2025.

Financial numbers in GBP

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Oct 26, 2026

Data Sources Report a data error